New chemo combo aims to stop leukemia return after transplant
NCT ID NCT01885689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewer side effects than standard treatments. Participants also receive drugs to prevent rejection and are followed for at least 2 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clofarabine and melphalan chemotherapy
- What this could lead to
- If successful, this approach could reduce the chance of leukemia returning after a stem cell transplant, with fewer side effects than standard treatments.
- What could go wrong
- This is a phase 2 trial with only 72 participants, so results may not apply to everyone. The chemotherapy itself can cause serious side effects, and the transplant carries risks like graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can donor immune cells tame stem cell transplant risks?
- Can a Two-Drug combo tame a rare blood cancer?